Stocks and Investing
Stocks and Investing
Wed, November 1, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Andrews Maintained (TGTX) at Strong Buy on, Nov 1st, 2023
Matthew Andrews of Jefferies, Maintained "TG Therapeutics, Inc." (TGTX) at Strong Buy on, Nov 1st, 2023.
Matthew has made no other calls on TGTX in the last 4 months.
There are 3 other peers that have a rating on TGTX. Out of the 3 peers that are also analyzing TGTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Decreased Target to $12 on, Thursday, August 3rd, 2023
These are the ratings of the 2 analyists that currently disagree with Matthew
- Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $24 on, Friday, October 20th, 2023
- Edward White of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $41 on, Monday, September 18th, 2023
Contributing Sources